PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem ...

Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr ...